Compare CHWY & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHWY | ALGN |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 10.5B |
| IPO Year | 2019 | 2000 |
| Metric | CHWY | ALGN |
|---|---|---|
| Price | $21.20 | $148.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 16 |
| Target Price | $28.64 | ★ $186.50 |
| AVG Volume (30 Days) | ★ 7.0M | 939.3K |
| Earning Date | 12-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.53 |
| EPS | 0.42 | ★ 3.09 |
| Revenue | ★ $12,601,500,000.00 | $387,126,000.00 |
| Revenue This Year | $7.32 | $2.24 |
| Revenue Next Year | $6.75 | $3.27 |
| P/E Ratio | ★ $49.71 | $49.72 |
| Revenue Growth | 6.24 | ★ 23.95 |
| 52 Week Low | $17.40 | $130.23 |
| 52 Week High | $37.34 | $200.44 |
| Indicator | CHWY | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 46.55 |
| Support Level | $19.78 | $138.05 |
| Resistance Level | $22.31 | $154.10 |
| Average True Range (ATR) | 0.78 | 4.69 |
| MACD | 0.09 | 0.72 |
| Stochastic Oscillator | 56.77 | 48.47 |
Founded in 2011, Chewy is a leading e-commerce retailer of pet food, toys, supplies, and medications in North America. The firm offers a comprehensive selection of proprietary and third-party brands, anchored by its highly sticky autoship subscription program, which drives over 83% of its sales. Beyond core retail, Chewy is expanding into high-margin revenue streams, including its retail media network (Chewy Ads), specialized veterinary healthcare software, and brick-and-mortar veterinary clinics to further integrate customers into the Chewy ecosystem.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.